Consolidated Statements of Changes Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Redemption Value Series 9 Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Balance at Dec. 31, 2022			$ 17,910		$ (32,893)	$ (14,983)
Balance (in Shares) at Dec. 31, 2022		12,727
Proceeds from sale of common stock			224			224
Proceeds from sale of common stock (in Shares)		64
Stock-based compensation			1,645			1,645
Issuance of warrants with convertible notes			968			968
JV obligation reclassified to equity			5,583			5,583
Net loss					(25,066)	(25,066)
Balance at Dec. 31, 2023			26,330		(57,959)	(31,629)
Balance (in Shares) at Dec. 31, 2023		12,791
Common and preferred shares issued via merger	$ 11,302		14,303			25,605
Common and preferred shares issued via merger (in Shares)	11,302	8,303
Common shares issued for net cash proceeds of ATM offering		$ 1	22,341			22,342
Common shares issued for net cash proceeds of ATM offering (in Shares)		998,447
Common shares issued as settlement of accrued compensation			4,398			4,398
Common shares issued as settlement of accrued compensation (in Shares)		193,716
Common shares issued as prepayment of services			335			335
Common shares issued as prepayment of services (in Shares)		1,718
Common shares issued to Xeriant, Inc.
Common shares issued to Xeriant, Inc. (in Shares)		1,194
Common shares issued in exchange of Series 9 preferred stock	$ (9,790)	$ 1	10,279			490
Common shares issued in exchange of Series 9 preferred stock (in Shares)	(9,790)	441,391
Accrued interest converted to Series 9 preferred stock	$ 576		26			602
Accrued interest converted to Series 9 preferred stock (in Shares)	576
Deemed dividend related to Series 9 preferred stock exchange			(490)			(490)
Redemption of Series 9 preferred stock	$ (757)		(38)			(795)
Redemption of Series 9 preferred stock (in Shares)	(757)
Series 9 preferred stock dividend accrual			(606)			(606)
Common shares issued for conversion of debt			9,612			9,612
Common shares issued for conversion of debt (in Shares)		11,551
Inducement loss on debt conversions			6,732			6,732
Common shares issued in exchange of warrants			1,982			1,982
Common shares issued in exchange of warrants (in Shares)		5,970
Deemed dividend related to December 2023 warrant exchange			(283)			(283)
Common shares issued for exercise of warrants			2			2
Common shares issued for exercise of warrants (in Shares)		82
Common shares issued for cashless exercise of warrants and options			1			1
Common shares issued for cashless exercise of warrants and options (in Shares)		1,928
Capital contribution - forgiveness of related party payable			380			380
Stock-based compensation			4,121			4,121
Stock-based compensation (in Shares)		7,930
Cumulative translation adjustment				(622)		(622)
Net loss					(35,603)	(35,603)
Balance at Dec. 31, 2024	$ 1,331	$ 2	$ 99,425	$ (622)	$ (93,562)	$ 6,574
Balance (in Shares) at Dec. 31, 2024	1,331	1,685,021